Ulcerative Colitis MY story

New Potential Drug

An currently under review for the treatment of rheumatoid arthritis has now shown positive results in patients with moderate to severe ulcerative colitis, according to researchers at the , School of Medicine.

The goal of this study is to show that the oral inhibitor is effective in treating ulcerative colitis. The next phase of studies aim to confirm the efficacy and safety profile of the drug, will examine the long term or maintenance effect of Tofacitinib and confirm the results of this study. This study has been funded by .

Results from the phase II clinical trial showed the drug Tofacitinib achieved clinical response and remission in certain patients suffering from ulcerative colitis — a of the colon where patients experience painful episodes of rectal bleeding and diarrhoea combined with the urgent need to use the restroom.

“Ulcerative colitis causes severe bouts of illness that adversely affect a patient’s quality of life at home and work,” said William Sandborn, MD, chief of the Division of at the UC School of Medicine and director of the Centre at UC San Diego Health System. “Oral treatment with Tofacitinib resulted in improvement and remission in some patients.”

Currently, there are limited types of drugs to treat ulcerative colitis. Drugs available are not universally effective and some require intravenous administration.

Ulcerative Colitis New Potential Drug

Ulcerative Colitis New Potential Drug

“This is a whole new class of drug that affects the number of proteins in the immune system that cause this type of inflammatory bowel disease,” said Sandborn. He further added, “Patients with a more advanced case of ulcerative colitis need a potent and highly effective therapy an the results of our study show Tofacitinib may provide a new approach to attacking this disease.”

One hundred and ninety four patients were part of the randomized trial, which was conducted at 51 centres in 17 countries. Eligible patients were at least 18 years of age, had a confirmed diagnosis of ulcerative colitis and had previously been treated with conventional therapy for the disease.

The patients were treated for eight weeks. They were given a dose of Tofacitinib twice daily, and benefits could be seen as early as two weeks. A flexile sigmoidoscopy was performed at the beginning and end of the trial, along with blood work and stool samples as a measurement of intestinal inflammation.

Among patients treated, the most commonly reported infections were influenza and nasopharyngitis — a respiratory infection with common-cold symptoms. Two patients developed an abscess, and in some cases, headaches were reported and the ulcerative colitis worsened.

Researchers who also participated in this study include Subrata Ghosh, MD, University of Calgary; Julian Panes, MD, Hospital Clinic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain; Ivana Vranic, Ph.D., Chinyu Su, MD, , MSc, and , MD, all at Pfizer Inc.

The Division of Gastroenterology at UC San Diego Health System is nationally recognized for its innovative and comprehensive care of patients by a multidisciplinary team of specialists in gastroenterology, endoscopy, oncology, surgery, transplantation and radiology.

Full article Researchers find potential drug for ulcerative colitis

About Robert Hill

I founded IDEAS Intestinal Disease Education and Awareness Society, from my home base in Vancouver, British Columbia. Intestinal Disease Education and Awareness Society IDEAS is established to raise public awareness of intestinal diseases in order to help remove the stigmas associated with these illnesses. The programs of IDEAS help children, youth and young adults learn to live full lives, find acceptance and gain confidence.

Leave a Reply